Hundreds of variants in “secondary finding” genes could guide treatment for patients to avoid risks and complications of health issues in adulthood.

Researchers at Children’s Hospital of Philadelphia (CHOP) revealed for the first time that children, adolescents and young adults may experience very rare neurological issues of paraparesis and quadriparesis following chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy used to treat B-cell Acute Lymphoblastic Leukemia (B-ALL). Additionally, these complications occurred without the type of inflammation typically seen in adults. The findings were published today in the journal Blood.

CHOP announced that its first patients outside of clinical trials have begun the treatment process for the newly FDA approved sickle cell gene therapies.

Dr. Scott Lorch of Children’s Hospital of Philadelphia (CHOP) invited to serve as a member of the Health Resources and Services Administration’s Advisory Committee on Infant and Maternal Mortality.

A gift from the Wyss Foundation elevates CHOP's research in thoracic insufficiency syndrome, a rare and complex condition.

At the Seating and Adaptive Equipment Clinic, Emma McKenzie, PT, DPT, works with children who have mobility issues.

Inspired by her own journey, a CHOP patient helps other children deal with the stress of managing an illness.

The Integrative Health Program empowers patients to take charge of their recovery.

CHOP researchers are aiming to treat a wider range of cancers by reaching previously “unreachable” drug targets.

A new partnership between CHOP and a local high school aims to lift families out of poverty.